Department of Ophthalmology, Gazi University School of Medicine, 06560, Ankara, Turkey.
Ulucanlar Eye Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
Int Ophthalmol. 2020 Aug;40(8):1969-1976. doi: 10.1007/s10792-020-01371-y. Epub 2020 Apr 19.
To evaluate the effect of topical tropicamide 1% and phenylephrine 2.5% instillation on macular and peripapillary microvasculature measurements with optical coherence tomography angiography (OCTA).
Forty eyes of 40 consecutive healthy adults with no known systemic or ocular disease were recruited for this prospective consecutive case study. After complete ophthalmological examination, all patients underwent OCTA measurements (OptoVue Inc, Freemont, CA, USA) to assess foveal avascular zone (FAZ) area, FAZ perimeter, acircularity index of FAZ, foveal density, vessel density of superficial and deep capillary plexus and peripapillary capillary plexus. 6 × 6 mm macular and 4.5 × 4.5 mm peripapillary OCTA images were undertaken before and 30 min after instillation of tropicamide (20 eyes) or phenylephrine (20 eyes) instillation to the right eye, and these were compared to each other and to fellow control eye.
15 male and 25 female patients with a mean age of 43.3 (18-60) years were recruited for the study. Superficial, deep and peripapillary capillary plexus measurements of tropicamide 1% and phenylephrine 2.5% instilled right eyes and left control eyes were similar before and 30 min after instillation (P > 0.05 for all). FAZ assessment tool variables were also similar before and after instillation (P > 0.05 for all) for both eyes.
Topical pupillary dilatation with tropicamide 1% and phenylephrine 2.5% did not affect macular and peripapillary OCTA measurements. Follow-up OCTA images in retina and glaucoma patients can be captured with a dilated or undilated pupil which seems not to be affected by tropicamide or phenylephrine.
评估 1%托吡卡胺和 2.5%苯肾上腺素滴眼对光学相干断层扫描血管造影（OCTA）黄斑和视盘周围微血管测量的影响。
本前瞻性连续病例研究招募了 40 名连续的健康成年人（40 只眼），他们均无已知的系统性或眼部疾病。在完成全面的眼科检查后，所有患者均接受 OCTA 测量（OptoVue Inc，弗里蒙特，加利福尼亚州，美国）以评估中心凹无血管区（FAZ）面积、FAZ 周长、FAZ 非圆度指数、中心凹密度、浅层和深层毛细血管丛以及视盘周围毛细血管丛的血管密度。在右眼滴入托吡卡胺（20 只眼）或苯肾上腺素（20 只眼）前后 30 分钟，对右眼和对侧对照眼分别进行 6×6mm 黄斑和 4.5×4.5mm 视盘 OCTA 成像，并对这些图像进行比较。
研究共纳入 15 名男性和 25 名女性患者，平均年龄为 43.3（18-60）岁。滴入托吡卡胺 1%和苯肾上腺素 2.5%前后，右眼和左眼对照眼的浅层、深层和视盘周围毛细血管丛的测量值相似（所有 P 值均>0.05）。滴入前后双眼 FAZ 评估工具变量也相似（所有 P 值均>0.05）。
1%托吡卡胺和 2.5%苯肾上腺素滴眼引起的瞳孔散大不会影响黄斑和视盘 OCTA 测量值。视网膜和青光眼患者的后续 OCTA 图像可以在瞳孔扩大或未扩大的情况下拍摄，似乎不受托吡卡胺或苯肾上腺素的影响。
